Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial

Reuters

Yesterday

Edgewise <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial

Edgewise Therapeutics Inc. announced the completion of Parts B and C and favorable interim safety results from Part D of the Phase 2 CIRRUS-HCM clinical trial evaluating EDG-7500, a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy $(HCM)$. According to the company, EDG-7500 was generally well tolerated in the ongoing study, with no clinically significant reductions in left ventricular ejection fraction (LVEF) observed. Comprehensive efficacy and safety data from Part D are expected to be presented in the second quarter of 2026. Edgewise Therapeutics plans to initiate a Phase 3 trial by the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53448) on December 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2593947290"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593947290\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593947290?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593947290","market":"fut","top_or_hot":-1,"title":"Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edgewise Therapeutics Inc. announced the completion of Parts B and C and favorable interim safety results from Part D of the Phase 2 CIRRUS-HCM clinical trial evaluating EDG-7500, a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy <a href=\"https://laohu8.com/S/HCM\">$(HCM)$</a>. According to the company, EDG-7500 was generally well tolerated in the ongoing study, with no clinically significant reductions in left ventricular ejection fraction (LVEF) observed. Comprehensive efficacy and safety data from Part D are expected to be presented in the second quarter of 2026. Edgewise Therapeutics plans to initiate a Phase 3 trial by the end of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53448) on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-24 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Edgewise Therapeutics Inc. announced the completion of Parts B and C and favorable interim safety results from Part D of the Phase 2 CIRRUS-HCM clinical trial evaluating EDG-7500, a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy <a href=\"https://laohu8.com/S/HCM\">$(HCM)$</a>. According to the company, EDG-7500 was generally well tolerated in the ongoing study, with no clinically significant reductions in left ventricular ejection fraction (LVEF) observed. Comprehensive efficacy and safety data from Part D are expected to be presented in the second quarter of 2026. Edgewise Therapeutics plans to initiate a Phase 3 trial by the end of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53448) on December 24, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nNDL891wT8:1","article_id":"2593947290","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593947290","pubTimestamp":1766581227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Edgewise Therapeutics Inc. announced the completion of Parts B and C and favorable interim safety results from Part D of the Phase 2 CIRRUS-HCM clinical trial evaluating EDG-7500, a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy . According to the company, EDG-7500 was generally well tolerated in the ongoing study, with no clinically significant reductions in left ventricular ejection fraction  observed. Comprehensive efficacy and safety data from Part D are expected to be presented in the second quarter of 2026. Edgewise Therapeutics plans to initiate a Phase 3 trial by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"Edgewise Therapeutics报告EDG-7500在2期CIRRUS-HCM试验中的积极中期安全性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":0.9},"content_text":"Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial\n    \n\n        Edgewise Therapeutics Inc. announced the completion of Parts B and C and favorable interim safety results from Part D of the Phase 2 CIRRUS-HCM clinical trial evaluating EDG-7500, a novel oral cardiac sarcomere modulator for hypertrophic cardiomyopathy $(HCM)$. According to the company, EDG-7500 was generally well tolerated in the ongoing study, with no clinically significant reductions in left ventricular ejection fraction (LVEF) observed. Comprehensive efficacy and safety data from Part D are expected to be presented in the second quarter of 2026. Edgewise Therapeutics plans to initiate a Phase 3 trial by the end of 2026.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA53448) on December 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}